Document is current
Any future updates will be listed below
-
Authors
Miñana, Gema
Valls, Neus
Lorenzo, Miguel
Núñez, Gonzalo
de la Espriella, Rafael
Mollar, Anna
Santas, Enrique
Núñez, Eduardo
Valero, Ernesto
Bodí, Vicent
Sanchis, Juan
Górriz, Jose Luis
Bayés-Genís, Antoni
Biegus, Jan
Núñez, Julio
-
Funding
Funding for this research was provided by:
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (16/11/00420 and 16/11/00403)
Instituto de Salud Carlos III (PIE15/00013 and PI17/01836)
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 19 March 2026
First Online: 14 May 2026
Declarations
:
: The authors declare no competing interests.
: Julio Núñez reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Rovi, and Vifor Pharma (outside the submitted work). Rafael de la Espriella reports personal fees from AstraZeneca, Novartis, Boehringer-Ingelheim, and NovoNordisk (outside the submitted work). Antoni Bayés-Genís has lectured and/or participated in Abbott, Astra Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Roche Diagnostics, and Vifor advisory boards (outside the submitted work). Jan Biegus has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures and from Alleviant Medical, Reprieve Cardiovascular and WhiteSwell for participation in clinical trial advisory boards. The remaining authors have no disclosures. There are no disclosures related to the content of this article.
